Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MABT5102A · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1: Subcutaneous cohort exp | EXPERIMENTAL | - |
| Part 2: Intravenous cohort exp | EXPERIMENTAL | - |
| Part 1: Subcutaneous cohort | PLACEBO_COMPARATOR | Repeating subcutaneous injection |
| Part 2: Intravenous cohort | PLACEBO_COMPARATOR | Repeating intravenous injection |
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MABT5102A | DRUG | Repeating subcutaneous injection |
| placebo | DRUG | Repeating subcutaneous injection |
Inclusion Criteria: * Diagnosis of probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorder Association (NINCDS-ADRDA) criteria * Mini-Mental State Examination (MMSE) score of 18-26 points at screening * ...
Top 20 of 24 competitors
MABT5102A is an investigational small molecule being studied for Alzheimer's disease and in healthy volunteers. It has been evaluated in clinical trials for mild to moderate Alzheimer's disease and in healthy volunteer studies to assess safety, tolerability, pharmacokinetics, and bioavailability.
MABT5102A is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company has sponsored clinical trials of this investigational drug in healthy volunteers and in patients with Alzheimer's disease.
MABT5102A has completed Phase 2 clinical trials for Alzheimer's disease. It is an investigational drug that has not been approved by regulatory authorities, and its development status reflects completed studies rather than an ongoing clinical program.
MABT5102A has been studied in three completed trials: NCT00997919, a Phase 1 study in healthy volunteers; NCT01343966, a Phase 2 efficacy and safety study in Alzheimer's disease; and NCT01397578, a Phase 2 study on brain amyloid load and biomarkers in Alzheimer's disease.
MABT5102A is an investigational drug being developed by Roche. It has been studied under this name in clinical trials for Alzheimer's disease. No alternative names have been established for this compound in the available clinical trial information.